Point72 Hong Kong’s Corvus Pharmaceuticals CRVS Stock Holding History

Point72 Hong Kong’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-527	Closed	-$6K	–	846
2017 Q2	$6K	Buy	+527	New	+$5.63K	0.01%	529

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Hong Kong's CRVS Position: Q3 2017 in Review

Point72 Hong Kong sold out of Corvus Pharmaceuticals (CRVS) in Q3 2017, closing a stake of 527 shares — an estimated $6K sold.

Point72 Hong Kong first reported a position in CRVS in Q2 2017 and held it in 1 quarter. The position peaked at $6K in Q2 2017. 54 funds tracked by Wall St. Rank hold CRVS as of Q3 2017.

Point72 Hong Kong reported no remaining Corvus Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Point72 Hong Kong sold 527 Corvus Pharmaceuticals shares in Q3 2017, an estimated $6K.
Point72 Hong Kong first reported a position in Corvus Pharmaceuticals in Q2 2017 and held it in 1 quarter.
Point72 Hong Kong's Corvus Pharmaceuticals position peaked at $6K in Q2 2017.
54 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2017.

Based on Point72 Hong Kong's 13F filing for Q3 2017, filed 14 Nov 2017.